Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432)
Xinghao Ai, Bo Jia, Zhiyi He, Junping Zhang, Minglei Zhuo, Jun Zhao, Zhe Wang, Jiexia Zhang, Zaiwen Fan, Xiaotong Zhang, Chong Li, Feng Jin, Ziming Li, Xia Ma, Hao Tang, Xiang Yan, Wei Li, Yuanyuan Xiong, Huan Yin, Rongrong Chen, Shun Lu · 2024
Read Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432) by Xinghao Ai, Bo Jia, Zhiyi He, Junping Zhang, Minglei Zhuo, Jun Zhao, Zhe Wang, Jiexia Zhang, Zaiwen Fan, Xiaotong Zhang, Chong Li, Feng Jin, Ziming Li, Xia Ma, Hao Tang, Xiang Yan, Wei Li, Yuanyuan Xiong, Huan Yin, Rongrong Chen, Shun Lu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11646999.txt.
Description
Xinghao Ai and co-authors test a blood-based model that spots early which lung cancer patients will gain lasting benefit from immune therapy. Their 2024 study is prospective and multicenter. Immune checkpoint drugs have reshaped care for non-small cell lung cancer, but many patients progress early despite treatment.
One hundred one patients without two key gene faults were enrolled from a screened pool of three hundred twenty-eight. Lasting benefit meant no progression for over six months, which fifty-six patients reached. The model blends a blood tumor mutation score, early changes in circulating tumor DNA, and the first scan response. It predicted lasting benefit with strong accuracy, and a second study cohort confirmed the result. Patients flagged as high risk could be switched sooner.
Catalog record
| CREATOR | Xinghao Ai, Bo Jia, Zhiyi He, Junping Zhang, Minglei Zhuo, Jun Zhao, Zhe Wang, Jiexia Zhang, Zaiwen Fan, Xiaotong Zhang, Chong Li, Feng Jin, Ziming Li, Xia Ma, Hao Tang, Xiang Yan, Wei Li, Yuanyuan Xiong, Huan Yin, Rongrong Chen, Shun Lu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |